Adamas Pharmaceuticals Inc 4
Accession 0001209191-16-141471
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 7:02 PM ET
Size
24.1 KB
Accession
0001209191-16-141471
Insider Transaction Report
- Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- Purchase
Common Stock
2016-09-13$15.56/sh+62,034$964,995→ 3,968,827 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Purchase
Common Stock
2016-09-12$15.65/sh+22,342$349,735→ 3,906,793 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP)
- 265,150(indirect: MDV VII, L.P.)
Common Stock
- 25,661(indirect: MDV VII Leaders' Fund, L.P.)
Common Stock
- 6,043(indirect: MDV ENF VII (A), L.P.)
Common Stock
- 3,146(indirect: MDV ENF VII (B), L.P.)
Common Stock
- 287,992(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.)
Common Stock
Footnotes (4)
- [F1]Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.26 and $15.75 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F2]Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F3]Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.25 and $16.00 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F4]Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
Documents
Issuer
Adamas Pharmaceuticals Inc
CIK 0001328143
Related Parties
1- filerCIK 0001328143
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 7:02 PM ET
- Size
- 24.1 KB